Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: Pooled analyses of phase II and III

Clinical and Experimental Rheumatology

Volumn 34, Issue 1, 2016, Pages 32-36

  Cohen, Stanley B ^a   Koenig, Andrew ^b   Wang, Lisy ^b   Kwok, Kenneth ^b   Mebus, Charles A ^b   Riese, Richard J ^b   Fleischmann, Roy M ^a  

^a METROPLEX CLINICAL RESEARCH CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

Arthritis; Rheumatoid; Treatment efficacy; United states

Indexed keywords

PLACEBO; TOFACITINIB; ANTIRHEUMATIC AGENT; JANUS KINASE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; ASIAN; BODY MASS; BODY WEIGHT; CAUCASIAN; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; HERPES ZOSTER; HUMAN; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; OPPORTUNISTIC INFECTION; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; TUBERCULOSIS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; ENZYMOLOGY; IMMUNOLOGY; META ANALYSIS; METABOLISM; ORAL DRUG ADMINISTRATION; PATIENT SAFETY; RISK ASSESSMENT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; JANUS KINASES; PATIENT SAFETY; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 84958777294     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. HELMICK CG, FELSON DT, LAWRENCE RC et al.: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58: 15-25.
2. FLEISCHMANN R, CUTOLO M, GENOVESE MC et al.: Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012; 64: 617-29.
3. KREMER JM, BLOOM BJ, BREEDVELD FC et al.: The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebocontrolled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009; 60: 1895-905.
4. KREMER JM, COHEN S, WILKINSON BE et al.: A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012; 64: 970-81.
5. McINNES IB, KIM HY, LEE SH et al.: Openlabel tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis 2014; 73:124-31.
6. TANAKA Y, SUZUKI M, NAKAMURA H, TOYOIZUMI S, ZWILLICH SH: Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011; 63: 1150-8.
7. TANAKA Y, TAKEUCHI T, YAMANAKA H et al.: Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol 2015; 25:514-21.
8. BURMESTER GR, BLANCO R, CHARLESSCHOEMAN C et al.: Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381: 451-60.
9. FLEISCHMANN R, KREMER J, CUSH J et al.: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367: 495-507.
10. van der HEIJDE D, TANAKA Y, FLEISCHMANN R et al.: Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65:559-70.
11. van VOLLENHOVEN RF, FLEISCHMANN R, COHEN S et al.: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-19.
12. KREMER J, LI ZG, HALL S et al.: Tofacitinib in combination with nonbiologic DMARDs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013; 159:253-61.
13. WOLLENHAUPT J, SILVERFIELD J, LEE EB et al.: Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014; 41:837-52.
14. SOKKA T, KAUTIAINEN H, PINCUS T et al.: Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 2009; 68: 1666-72.